Order Article Reprints

Schokker S, van der Woude SO, van Kleef JJ, van Zoen DJ, van Oijen MGH, Mearadji B, Beenen LFM, Stroes CI, Waasdorp C, Jibodh RA, et al. Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers. 2019; 11(6):827. https://doi.org/10.3390/cancers11060827

Schokker, Sandor, Stephanie O. van der Woude, Jessy Joy van Kleef, Daan J. van Zoen, Martijn G. H. van Oijen, Banafsche Mearadji, Ludo F. M. Beenen, Charlotte I. Stroes, Cynthia Waasdorp, R. Aarti Jibodh, and et al. 2019. "Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)" Cancers 11, no. 6: 827. https://doi.org/10.3390/cancers11060827

Schokker, S., van der Woude, S. O., van Kleef, J. J., van Zoen, D. J., van Oijen, M. G. H., Mearadji, B., Beenen, L. F. M., Stroes, C. I., Waasdorp, C., Jibodh, R. A., Creemers, A., Meijer, S. L., Hooijer, G. K. J., Punt, C. J. A., Bijlsma, M. F., & van Laarhoven, H. W. M. (2019). Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study). Cancers, 11(6), 827. https://doi.org/10.3390/cancers11060827